Trials / Withdrawn
WithdrawnNCT04309734
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
A Phase I/IIa Study Assessing AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Atea Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study has two parts. Part A will assess the safety, tolerability and pharmacokinetics (PK) of AT-777 in healthy subjects. Part B will assess the safety, antiviral activity/efficacy and PK of AT-777 in combination with AT-527 after 8 weeks of treatment in HCV-infected subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AT-777 | Administered orally as one or two 60 mg capsule(s) of AT-777 (inhibitor of HCV nonstructural protein 5A (NS5A)), depending on the arm. |
| DRUG | Placebo | Administered orally, as one or two placebo capsules, depending on the arm. |
| DRUG | AT-527 | Administered orally as one 550 mg tablet of AT-527 (nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase), depending on the arm. |
Timeline
- Start date
- 2021-10-01
- Primary completion
- 2022-06-01
- Completion
- 2022-09-01
- First posted
- 2020-03-16
- Last updated
- 2022-06-08
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT04309734. Inclusion in this directory is not an endorsement.